Loading…

Macrophage/microglia-derived IL-1β induces glioblastoma growth via the STAT3/NF-κB pathway

Glioblastoma is a glioma characterized by highly malignant features. Numerous studies conducted on the relationship between glioblastoma and the microenvironment have indicated the significance of tumor-associated macrophages/microglia (TAMs) in glioblastoma progression. Since interleukin (IL)-1β se...

Full description

Saved in:
Bibliographic Details
Published in:Human cell : official journal of Human Cell Research Society 2022-01, Vol.35 (1), p.226-237
Main Authors: Kai, Keitaro, Komohara, Yoshihiro, Esumi, Shigeyuki, Fujiwara, Yukio, Yamamoto, Takahiro, Uekawa, Ken, Ohta, Kazutaka, Takezaki, Tatsuya, Kuroda, Junichiro, Shinojima, Naoki, Hamasaki, Tadashi, Mukasa, Akitake
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glioblastoma is a glioma characterized by highly malignant features. Numerous studies conducted on the relationship between glioblastoma and the microenvironment have indicated the significance of tumor-associated macrophages/microglia (TAMs) in glioblastoma progression. Since interleukin (IL)-1β secreted by TAMs has been suggested to promote glioblastoma growth, we attempted to elucidate the detailed mechanisms of IL-1β in glioblastoma growth in this study. A phospho-receptor tyrosine kinase array and RNA-sequencing studies indicated that IL-1β induced the activation of signal transducer and activator of transcription-3 and nuclear factor-kappa B signaling. Glioblastoma cells stimulated by IL-1β induced the production of IL-6 and CXCL8, which synergistically promoted glioblastoma growth via signal transducer and activator of transcription-3 and nuclear factor-kappa B signaling. By immunohistochemistry, IL-1β expression was seen on TAMs, especially in perinecrotic areas. These results suggest that IL-1β might be a useful target molecule for anti-glioblastoma therapy.
ISSN:1749-0774
0914-7470
1749-0774
DOI:10.1007/s13577-021-00619-8